ORGANIZATION
Industry Leaders Issue Statements on FY2020 Reform Package; Improved PMP Criteria Given Certain Credit
Pharma industry chieftains on December 20 issued their statements for a package of reform plans approved on the day for the FY2020 drug pricing reform next April, with proposed revisions to the price maintenance premium (PMP) credited as “a certain…
To read the full story
Related Article
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
ORGANIZATION
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
- APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





